God morgen.

]]>https://dev.proinvestor.com/forum/topic/451534/genmab-september-2019RSS for NodeSat, 13 Jun 2026 17:53:50 GMTSun, 01 Sep 2019 04:10:36 GMT60Men tilbage til virkeligheden. 100% lysis er sjælden at se jf tidligere omtalte fig B

]]>https://dev.proinvestor.com/forum/post/10214514https://dev.proinvestor.com/forum/post/10214514Mon, 30 Sep 2019 16:31:32 GMTJeg tvivler stadig på at Genmab er selvstændig, når vi når der til. Så siger jeg ikke mere

]]>https://dev.proinvestor.com/forum/post/10214516https://dev.proinvestor.com/forum/post/10214516Mon, 30 Sep 2019 16:28:15 GMTMon der vil være kumulativ effekt på de to cd38 stoffer ?

]]>https://dev.proinvestor.com/forum/post/10214513https://dev.proinvestor.com/forum/post/10214513Mon, 30 Sep 2019 16:26:26 GMTJeg kan få våde drømme om en kombi med hexa cd38 (20% flat royalty) og den nye dara + en af duobodierne. Men om det overhovedet kan lade sig gøre, aner jeg ikke.

]]>https://dev.proinvestor.com/forum/post/10214515https://dev.proinvestor.com/forum/post/10214515Mon, 30 Sep 2019 16:13:35 GMTJo det er heller ikke noget der er risiko for i morgen. Regner da også med at Genmab ikke laver selvmål

]]>https://dev.proinvestor.com/forum/post/10214510https://dev.proinvestor.com/forum/post/10214510Mon, 30 Sep 2019 16:02:01 GMTIndtil videre er der jo kun tale om at bruge dem som som monoterapi, når alt andet - incl cd38 antistoffer - er holdt op med at virke.

]]>https://dev.proinvestor.com/forum/post/10214512https://dev.proinvestor.com/forum/post/10214512Mon, 30 Sep 2019 15:54:31 GMTMan kunne godt blive nervøs for at Genmab selv har udviklet konkurrenter til dara...

]]>https://dev.proinvestor.com/forum/post/10214511https://dev.proinvestor.com/forum/post/10214511Mon, 30 Sep 2019 15:00:26 GMThttps://journals.lww.com/hemasphere/fulltext/2019/06001/PRECLINICAL_EVALUATION_OF_THE_NEW_GPRC5DXCD3.454.aspx Se bl.a. fig B

]]>https://dev.proinvestor.com/forum/post/10214505https://dev.proinvestor.com/forum/post/10214505Mon, 30 Sep 2019 14:56:13 GMTBegge targets tror jeg er interessante og at vi må forvente at begge duobodies har acceptable bivirkningsprofiler indtil nu er jo meget opløftende som investor.

]]>https://dev.proinvestor.com/forum/post/10214503https://dev.proinvestor.com/forum/post/10214503Mon, 30 Sep 2019 14:08:33 GMTDet er jo det her vi har set langt efter. En dara-duo-kombi!

]]>https://dev.proinvestor.com/forum/post/10214508https://dev.proinvestor.com/forum/post/10214508Mon, 30 Sep 2019 14:05:20 GMTExactly. And keep GSK away with their BCMA. The target seem very good to get effect but duration is darzalex issue.

]]>https://dev.proinvestor.com/forum/post/10214507https://dev.proinvestor.com/forum/post/10214507Mon, 30 Sep 2019 13:56:02 GMTThe study has Estimated Primary Completion Date in January 2021. With luck we'll have results at ASH next year.

]]>https://dev.proinvestor.com/forum/post/10214509https://dev.proinvestor.com/forum/post/10214509Mon, 30 Sep 2019 13:53:21 GMT@Bulder I thought it was slightly higher, but even 7% is more then what we get on
Lenalidomide

]]>https://dev.proinvestor.com/forum/post/10214506https://dev.proinvestor.com/forum/post/10214506Mon, 30 Sep 2019 13:51:53 GMTJNJ could be on the track to unload bn of dollers to Genmab

]]>https://dev.proinvestor.com/forum/post/10214501https://dev.proinvestor.com/forum/post/10214501Mon, 30 Sep 2019 13:47:40 GMTSalamanca is one of the locations, so Prof Maria-Victoria Mateos is involved. Can't go wrong then.

]]>https://dev.proinvestor.com/forum/post/10214502https://dev.proinvestor.com/forum/post/10214502Mon, 30 Sep 2019 13:45:39 GMTVery good for Genmab if they turns out
to be positve combinations

]]>https://dev.proinvestor.com/forum/post/10214500https://dev.proinvestor.com/forum/post/10214500Mon, 30 Sep 2019 13:42:13 GMTBut genmab doesn't get as much royalty from the duobodies? Was it 7%?

]]>https://dev.proinvestor.com/forum/post/10214498https://dev.proinvestor.com/forum/post/10214498Mon, 30 Sep 2019 13:41:25 GMTagree

]]>https://dev.proinvestor.com/forum/post/10214504https://dev.proinvestor.com/forum/post/10214504Mon, 30 Sep 2019 13:39:42 GMTthis could turn out to be a great move by JNJ. 1 package JNJ solution.

]]>https://dev.proinvestor.com/forum/post/10214499https://dev.proinvestor.com/forum/post/10214499Mon, 30 Sep 2019 13:38:11 GMTthat can still come Bulder

]]>https://dev.proinvestor.com/forum/post/10214497https://dev.proinvestor.com/forum/post/10214497Mon, 30 Sep 2019 13:36:50 GMTsorry, not doubled, but increased

]]>https://dev.proinvestor.com/forum/post/10214495https://dev.proinvestor.com/forum/post/10214495Mon, 30 Sep 2019 13:36:42 GMTCould have been interesting with dara sc and a duobody sc as well.

]]>https://dev.proinvestor.com/forum/post/10214494https://dev.proinvestor.com/forum/post/10214494Mon, 30 Sep 2019 13:36:11 GMTthe BCMA CD3 also doubled https://clinicaltrials.gov/ct2/history/NCT03145181?A=17&B=18&C=merged#StudyPageTop

]]>https://dev.proinvestor.com/forum/post/10214491https://dev.proinvestor.com/forum/post/10214491Mon, 30 Sep 2019 13:35:46 GMTThey have Primary Completion Date later this year or next year. So maybe they have seen satisfying safety results already.

]]>https://dev.proinvestor.com/forum/post/10214496https://dev.proinvestor.com/forum/post/10214496Mon, 30 Sep 2019 13:35:06 GMT